American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: Editor-in-chief: Apply for this position
Open Access
Journal Browser
American Journal of Medical Case Reports. 2021, 9(8), 424-427
DOI: 10.12691/ajmcr-9-8-10
Open AccessCase Report

Guillain-Barré Syndrome in a 67-year-old Male Post COVID-19 Vaccination (Astra Zeneca)

Silfat Azam1, Abdalla Khalil1, and Ahmad Taha2

1Acute Medicine Department, Princess Royal University Hospital, King’s college trust, London BR6 8ND, UK

2Radiology Department, Princess Royal University Hospital, King’s College trust, London BR6 8ND, UK

Pub. Date: May 10, 2021

Cite this paper:
Silfat Azam, Abdalla Khalil and Ahmad Taha. Guillain-Barré Syndrome in a 67-year-old Male Post COVID-19 Vaccination (Astra Zeneca). American Journal of Medical Case Reports. 2021; 9(8):424-427. doi: 10.12691/ajmcr-9-8-10


Since the COVID-19 pandemic has started in December 2019, millions of people have been infected all over the world and few vaccines have been invented recently. Extremely rare, Guillain-Barre Syndrome (GBS) was reported as a neurological complication after H1N1 flu vaccination. Currently, Pfizer and AstraZeneca vaccines are available to prevent infection with COVID-19. The first case of post-COVID-19 vaccine GBS has been detected in a secondary care hospital after vaccination with AstraZeneca. A 67-year-old man presented with an acute progressive ascending flaccid symmetrical motor neuropathy, and bilateral facial weakness which developed two weeks after receiving the first dose of AstraZeneca COVID-19 vaccine. His cerebrospinal fluid findings, nerve conduction result, and MRI brain result were all in favour of GBS diagnosis. The patient’s workup for all known infections associated with immune-mediated GBS was negative.

COVID-19 infection COVID-19 vaccine Guillain-Barre Syndrome (GBS) Miller Fisher Syndrome (MFS)

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Kuwabara S, Yuki N. Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol. 2013 Dec; 12(12): 1180-8.
[2]  Brannagan TH 3rd, Zhou Y. HIV-associated Guillain-Barré syndrome. J Neurol Sci. 2003 Apr 15; 208(1-2): 39-42.
[3]  Lehmann HC, Hartung HP, Kieseier BC, Hughes RA. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis. 2010 Sep; 10(9): 643-51.
[4]  Steininger C, Popow-Kraupp T, Seiser A, Gueler N, Stanek G, Puchhammer E. Presence of cytomegalovirus in cerebrospinal fluid of patients with Guillain-Barre syndrome. J Infect Dis. 2004 Mar 15; 189(6): 984-9.
[5]  Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, Franciotta D et al. Guillain-Barré Syndrome Associated with SARS-CoV-2. N Engl J Med. 2020 Jun 25; 382(26): 2574-2576
[6]  Webb S, Wallace VC, Martin-Lopez D, Yogarajah M. Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication. BMJ Case Rep. 2020 Jun 14; 13(6): e236182.
[7]  Shoamanesh A, Chapman K, Traboulsee A. Postvaccination Miller Fisher syndrome. Arch Neurol. 2011 Oct; 68(10): 1327-9.
[8]  Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry. 1998 Jan; 64(1): 74-7.
[9]  Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018 Oct 1; 141(10): 2866-2877.
[10]  Anandan C, Khuder SA, Koffman BM. Prevalence of autonomic dysfunction in hospitalized patients with Guillain-Barré syndrome. Muscle Nerve. 2017 Aug; 56(2): 331-333.
[11]  Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012 Jun 14; 366(24): 2294-304.
[12]  McCarthy N, Giesecke J. Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol. 2001 Mar 15; 153(6): 610-4.
[13]  Rahimi K. Guillain-Barre syndrome during COVID-19 pandemic: an overview of the reports. Neurol Sci. 2020 Nov; 41(11): 3149-3156.
[14]  Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR et al. H1N1 GBS Meta-Analysis Working Group. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 2013 Apr 27; 381(9876): 1461-8.
[15]  Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med. 2006 Jun 26; 166(12): 1301-4.
[16]  Sadia Waheed, Angel Bayas, Fawzi Hindi, Zufe Rizvi, Patricio S. Espinosa. Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine. Cureus 13(2): e13426.